AstraZeneca Plc $AZN Stock Sold by Choreo LLC

Choreo LLC decreased its position in shares of AstraZeneca Plc (NYSE:AZN) by 25.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,659 shares of the company’s stock after selling 5,281 shares during the period. Choreo LLC’s holdings in AstraZeneca were worth $2,520,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of AZN. Mascoma Wealth Management LLC purchased a new stake in shares of AstraZeneca in the first quarter valued at $26,000. Roxbury Financial LLC purchased a new position in AstraZeneca during the second quarter worth about $29,000. Laurel Wealth Advisors LLC purchased a new position in AstraZeneca during the third quarter worth about $30,000. GK Wealth Management LLC acquired a new stake in AstraZeneca in the 3rd quarter worth about $31,000. Finally, Lynch Investment Planning LLC acquired a new stake in AstraZeneca in the 3rd quarter worth about $32,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on AZN shares. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. CICC Research assumed coverage on shares of AstraZeneca in a research report on Sunday, August 23rd. They set an “outperform” rating and a $198.00 price target for the company. Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Tuesday, October 6th. Zacks Research raised shares of AstraZeneca from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 13th. Finally, Wall Street Zen upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Saturday. Sixteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $206.67.

AstraZeneca News Roundup

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Q3 earnings beat expectations: Core EPS reached $2.79 versus the roughly $2.60 analyst consensus, while revenue increased about 7% year over year to $16.21 billion, topping estimates near $16 billion. Net profit rose to $3.12 billion from $2.54 billion a year earlier. AstraZeneca Stock Rallies on Q3 Earnings Beat
• Positive Sentiment: Oncology remains the key growth engine: Cancer-drug sales rose 17%, helping offset generic competition and declining sales from mature medicines such as Farxiga. The performance suggests AstraZeneca’s newer products are mitigating patent-cliff pressure. AZN Q3 Earnings Beat Estimates
• Positive Sentiment: Pipeline catalysts support the longer-term story: Management highlighted more than $20 billion of potential from 2027 drug-trial readouts, while the company reported 12 positive Phase 3 readouts. These catalysts could expand AstraZeneca’s growth prospects beyond its current portfolio. AstraZeneca CEO Sees Over $20B Potential
• Positive Sentiment: Guidance was reaffirmed: AstraZeneca maintained its fiscal 2026 outlook for mid-to-high single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates. The company also targeted $1.5 billion in annual savings, potentially supporting margins and earnings. AstraZeneca Reports Q3 Revenue Growth
• Neutral Sentiment: Analyst views remain mixed: Guggenheim maintained a Buy rating, while Deutsche Bank retained Hold and Erste Group Bank lowered its FY2026 EPS estimate, indicating some valuation and execution concerns remain. Guggenheim Maintains Buy Rating
• Negative Sentiment: Generic competition remains a headwind: Farxiga and other mature products face pricing and volume pressure, which could limit growth if newer oncology and pipeline medicines do not continue to scale. AstraZeneca Holds Guidance

AstraZeneca Price Performance

AstraZeneca stock opened at $186.49 on Friday. The firm has a fifty day moving average of $164.48 and a 200-day moving average of $180.21. AstraZeneca Plc has a 52-week low of $153.41 and a 52-week high of $212.71. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $289.23 billion, a P/E ratio of 26.38, a PEG ratio of 1.45 and a beta of 0.27.

AstraZeneca (NYSE:AZN) last posted its earnings results on Friday, October 30th. The company reported $2.79 earnings per share for the quarter, beating the consensus estimate of $2.60 by $0.19. AstraZeneca had a net margin of 17.02% and a return on equity of 31.45%. The business had revenue of $16.21 billion for the quarter, compared to analyst estimates of $16 billion. During the same quarter in the previous year, the business posted $2.38 EPS. The business’s quarterly revenue was up 6.5% on a year-over-year basis. As a group, analysts predict that AstraZeneca Plc will post 10.21 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.